Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00129259 · ClinicalTrials.gov registry record · Phase 2
Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 83
- Enrollment target
NCT00129259 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 83 participants.
The verdict
NCT00129259, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 83 participants
- Enrollment target
Study Summary
Anti-CD3 monoclonal antibody (a.k.a. hOKT3gamma1 \[Ala-Ala\],teplizumab, MGA031) is a humanized antibody that is commonly used to prevent organ rejection. The purpose of this study is determine whether anti-CD3 mAb treatment can halt the progression of newly diagnosed type 1 diabetes.
Interventions
- BIOLOGICAL Anti-CD3 mAb
- OTHER Diabetes Standard of Care Treatment
- DIETARY_SUPPLEMENT Iron supplementation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2005-09 |
| Est. Completion | 2011-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00129259
The ClinicalTrials.gov registry entry for NCT00129259 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Anti-CD3 mAb is the first listed.
NCT00129259 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00129259 about?
NCT00129259 is a clinical study titled "Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes". Anti-CD3 monoclonal antibody (a.k.a. hOKT3gamma1 \[Ala-Ala\],teplizumab, MGA031) is a humanized antibody that is commonly used to prevent organ rejection. The purpose of this study is determine whether anti-CD3 mAb treatment can halt the progression of newly diagnosed type 1 diabetes.
What is the current status of trial NCT00129259?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 83 participants. The study started on 2005-09. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00129259?
The interventions under investigation include: Anti-CD3 mAb (BIOLOGICAL), Diabetes Standard of Care Treatment (OTHER), Iron supplementation (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00129259?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.